Skip to main content
OpenTrials
Completed

NCT Number: NCT04884256

Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula

STUDY DESIGN:

Structure:

Multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.

Duration of Treatment:

4 weeks of study treatment with 4 weeks follow-up observations.

Control:

Vehicle for CBT-004 (hereafter referred to as Vehicle).

Masking:

Subjects, Investigators, Study Monitors and the Independent Image Reading Center are all masked to the study medications.

Dosage/Dose regimen:

One drop of the assigned study medication will be administered in the study eye TID for 4 weeks. The study eye is defined as the qualified eye (i.e., the eye meeting the inclusion criterion for vascularized pinguecula). If both eyes are qualified, then the eye with the more severe vascularity grade at Visit 1 will be the study eye.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pinguecula Conjunctival Diseases Eye Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Global Research Management

Glendale, California, 91204, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pinguecula with a vascularity grade ≥ 3 on a 5-point (0-4) scale.
  • Ocular bothersome questionnaire score ≥ 2 on a 5-point (0-4) scale.
  • ≥ 18 years of age.
  • Able to provide written informed consent and comply with study assessments for the full duration of the study.

Exclusion criteria

  • Uncontrolled systemic disease, in the opinion of the investigator.
  • Active ocular disease other than pinguecula that may confound the study data, including but not limited to severe dry eye disease, pterygium, uncontrolled blepharitis, anterior membrane dystrophy, Salzmann's, glaucoma, or active ocular infection.
  • History of ocular herpes disease, iritis/uveitis, in either eye.
  • Any ocular surgical procedure within the last 3 months or anticipated ocular surgery during the study, in either eye.
  • Anticipated wearing of contact lenses during any portion of the study. Patients, who wear soft contact lenses should discontinue wearing them at least 7 days prior to Day 1 visit. Patients wearing rigid gas permeable or hard contact lenses should discontinue wearing them at least 3 weeks prior to Day 1 visit.
  • Female patients who are pregnant, nursing, or planning a pregnancy during the study.
  • Current enrollment in an investigational drug or device study or participation in such a study within 30 days prior to entry into this study.
  • History of myocardial infarction or stroke.
  • Any condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study.
  • Known allergy or sensitivity to the study medication(s) or its components.
  • Current or anticipated use of topical ophthalmic medications in the study eye. Patients must have discontinued use of ophthalmic medications in the study eye for at least 2 weeks (4 weeks for Restasis® or Xiidra®) prior to Day 1 visit. Artificial tears are allowed in the study eye until 7 days prior to Visit 1 and should not be used during the treatment phase of the study.

Treatment and study plan

CBT-004

Drug

Dose response study

Primary outcomes

  1. Change from Baseline in conjunctival hyperemia grade at Day 28 (Week 4).

    Time frame: 1 month

Secondary outcomes

  1. Change from Baseline conjunctival hyperemia digital image grade at Days 7 (Week 1) and 56 (Week 8).

    Time frame: 2 month

Sponsors and collaborators

Lead sponsor

Cloudbreak Therapeutics, LLC

Industry

Registry information

Official study title

A Phase 2 Multicenter, Randomized, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of CBT-004 Ophthalmic Emulsion in Patients With Vascularized Pinguecula

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
May 12, 2021
Registry last updated
Jun 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.